Wuwu Biotech announced that Zhejiang Wuwu Stem Cell Technology Co., Ltd., an indirect holding subsidiary of the company, previously withdrew the drug clinical trial application and submitted it again after completing the relevant pharmaceutical research. Recently, it obtained the “Notice of Acceptance” issued by the State Drug Administration, and its application for clinical trials of the “human umbilical cord mesenchymal stem cell type II injection” drug was officially accepted.

Wuwu Biotech announced that Zhejiang Wuwu Stem Cell Technology Co., Ltd., an indirect holding subsidiary of the company, previously withdrew the drug clinical trial application and submitted it again after completing the relevant pharmaceutical research. Recently, it obtained the “Notice of Acceptance” issued by the State Drug Administration, and its application for clinical trials of the “human umbilical cord mesenchymal stem cell type II injection” drug was officially accepted.